Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance

Abstract

Gemcitabine is a cytidine analogue frequently used in the treatment of various cancers. However, the development of chemoresistance limits its effectiveness. Gemcitabine resistance is regulated by various factors, including aberrant genetic and epigenetic controls, metabolism of gemcitabine, the microenvironment, epithelial-to-mesenchymal transition, and acquisition of cancer stem cell properties. In many situations, results using cell lines offer valuable lessons leading to the first steps of important findings. In this review, we mainly discuss the factors involved in gemcitabine metabolism in association with chemoresistance, including nucleoside transporters, deoxycytidine kinase, cytidine deaminase, and ATP-binding cassette transporters, and outline new perspectives for enhancing the efficacy of gemcitabine to overcome acquired chemoresistance.

Keywords

Gemcitabine / chemoresistance / deoxycytidine kinase / human equilibrative nucleoside transporter 1 / cytidine deaminase / ATP-binding cassette transporters / metabolism

References

[1] Bonjouklian R,Kuhler KM,Poore GA.Studies of the antitumor activity of (2-alkoxyalkyl)- and (2-alkoxyalkenyl)phosphocholines..J Med Chem1986;29:2472-7

[2] Heinemann V,Grindey GB.Comparison of the cellular pharmacokinetics and toxicity of 2’,2’-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine..Cancer Res1988;48:4024-31

[3] Boswell-Casteel RC.Equilibrative nucleoside transporters-a review..Nucleosides Nucleotides Nucleic Acids2017;36:7-30 PMCID:PMC5728162

[4] Shimada T,Tajima H,Yokono R.Saturable hepatic extraction of gemcitabine involves biphasic uptake mediated by nucleoside transporters Equilibrative Nucleoside Transporter 1 and 2..J Pharm Sci2015;104:3162-9

[5] Mini E,Caciagli B,Mazzei T.Cellular pharmacology of gemcitabine..Ann Oncol.2006;17 Suppl 5:v7-12

[6] Ruiz van Haperen VW,Vermorken JB.2’,2’-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines..Biochem Pharmacol1993;46:762-6

[7] Bergman AM,Peters GJ.Determinants of resistance to 2’,2’-difluorodeoxycytidine (gemcitabine)..Drug Resist Updat2002;5:19-33

[8] Kroep JR,Tolis C,Loves WJ.Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines..Br J Cancer2000;83:1069-76 PMCID:PMC2363564

[9] Honeywell RJ,Veerman G,Peters GJ.Inhibition of thymidylate synthase by 2’,2’-difluoro-2’-deoxycytidine (Gemcitabine) and its metabolite 2’,2’-difluoro-2’-deoxyuridine..Int J Biochem Cell Biol2015;60:73-81

[10] Motoi F.Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?.Ann Gastroenterol Surg2020;4:100-8 PMCID:PMC7105839

[11] Gesto DS,Fernandes PA.Gemcitabine: a critical nucleoside for cancer therapy..Curr Med Chem2012;19:1076-87

[12] Kelderman S,Haanen JB.Acquired and intrinsic resistance in cancer immunotherapy..Mol Oncol2014;8:1132-9 PMCID:PMC5528612

[13] Zheng X,Kim J,Kaye J.Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer..Nature2015;527:525-30 PMCID:PMC4849281

[14] Arumugam T,Fournier KF,Marquis L.Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer..Cancer Res2009;69:5820-8 PMCID:PMC4378690

[15] Fang Y,Rong Y,Xu X.Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer..Exp Cell Res2019;383:111543

[16] Yang Z,Cui J,Xiong J.Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210..Cell Oncol (Dordr)2020;43:123-36

[17] Ritzel MW,Yao SY,Loewen SK.Recent molecular advances in studies of the concentrative Na+-dependent nucleoside transporter (CNT) family: identification and characterization of novel human and mouse proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)..Mol Membr Biol2001;18:65-72

[18] Lostao MP,Larrayoz IM,Casado FJ.Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes..FEBS Lett2000;481:137-40

[19] Mackey JR,Selner M,Young JD.Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines..Cancer Res1998;58:4349-57

[20] Garcia-Manteiga J,Casado FJ,Pastor-Anglada M.Nucleoside transporter profiles in human pancreatic cancer cells: Role of hCNT1 in 2’,2’-difluorodeoxycytidine- induced cytotoxicity..Clin Cancer Res2003;9:5000-5008

[21] Rauchwerger DR,Hedley DW.Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity..Cancer Res2000;60:6075-9

[22] Mohelnikova-Duchonova B.Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients?.Pancreatology2013;13:558-63

[23] Orlandi A,Martini M,Bagala C.Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse..Clin Transl Oncol2016;18:988-95

[24] Bird NT,Jones R,Dodd J.Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy..Br J Surg2017;104:328-36

[25] Nishio R,Yasui T,Kanki K.Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd)..Cancer Sci2011;102:622-9

[26] Mohelnikova-Duchonova B,Oliverius M,Kala Z.Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues..Pancreas2013;42:707-16

[27] Bhutia YD,Patel B,Govindarajan R.CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells..Cancer Res2011;71:1825-35 PMCID:PMC3048166

[28] Skrypek N,Hebbar M,van Seuningen I.The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family..Oncogene2013;32:1714-23 PMCID:PMC3936121

[29] Chen P,Khan AR,Ali SM.In vitro and in vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate..Anticancer Drugs2006;17:53-61

[30] Bergman AM,Balzarini J,Fichtner I.Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models..Invest New Drugs2011;29:456-66 PMCID:PMC3076580

[31] Poplin E,Rolfe L,Ikdahl T.Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity..J Clin Oncol2013;31:4453-61

[32] Raffenne J,Puleo F,Boyez C.hENT1 testing in pancreatic ductal adenocarcinoma: are we ready? a multimodal evaluation of hENT1 status..Cancers (Basel)2019;11: PMCID:PMC6896053

[33] Guo Z,Di Y,Yu X.Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression..Int J Nanomedicine2018;13:4869-80 PMCID:PMC6122898

[34] Couvreur P,Reddy LH,Dubernet C.Squalenoyl nanomedicines as potential therapeutics..Nano Lett2006;6:2544-8

[35] Bildstein L,Marsaud V,Nicolas V.Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway..J Control Release2010;147:163-70

[36] Chitkara D,Behrman SW,Mahato RI.Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma..Bioconjug Chem2013;24:1161-73

[37] Wonganan P,Zhu S,Sandoval MA.Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle’s ability to overcome gemcitabine resistance caused by RRM1 overexpression..J Control Release2013;169:17-27 PMCID:PMC3683387

[38] Frances A.The emerging role of cytidine deaminase in human diseases: a new opportunity for therapy?.Mol Ther2020;28:357-66 PMCID:PMC7001087

[39] Heinemann V,Chubb S,Hertel LW.Cellular elimination of 2’,2’-difluorodeoxycytidine 5’-triphosphate: a mechanism of self-potentiation..Cancer Res1992;52:533-9

[40] Abbruzzese JL,Weeks EA,Adams T.A phase I clinical, plasma, and cellular pharmacology study of gemcitabine..J Clin Oncol1991;9:491-8

[41] Chalmers IM,Desjardins P.Serum cytidine deaminase as a laboratory test for acute inflammation in rheumatoid arthritis..Ann Rheum Dis1988;47:173-4 PMCID:PMC1003474

[42] Peters GJ,Maulandi M,Losekoot N.Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment..Nucleosides Nucleotides Nucleic Acids2014;33:403-12

[43] Sugiyama E,Kim SR,Saito Y.Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms..Clin Pharmacokinet2010;49:549-58

[44] Micozzi D,Pucciarelli S,Polidori P.Human cytidine deaminase: a biochemical characterization of its naturally occurring variants..Int J Biol Macromol2014;63:64-74 PMCID:PMC3904506

[45] Serdjebi C,Ciccolini J,Norguet E.Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen..Pharmacogenomics2013;14:1047-51

[46] Ding X,Fan H.Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy..Gene2015;559:31-7

[47] Neff T.Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine..Exp Hematol1996;24:1340-6

[48] van Haperen VW,Vermorken JB,Peters G.Regulation of phosphorylation of deoxycytidine and 2’,2’-difluorodeoxycytidine (gemcitabine); effects of cytidine 5’-triphosphate and uridine 5’-triphosphate in relation to chemosensitivity for 2’,2’-difluorodeoxycytidine..Biochem Pharmacol1996;51:911-8

[49] Ruiz van Haperen VW,Braakhuis BJ,Boven E.Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts..Eur J Cancer1993;29A:2132-7

[50] Mameri H,Meseure D,Buhagiar-Labarchede G.Cytidine deaminase deficiency reveals new therapeutic opportunities against cancer..Clin Cancer Res2017;23:2116-26 PMCID:PMC7430158

[51] Zauri M,Thezenas ML,Goldin R.CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer..Nature2015;524:114-8 PMCID:PMC4866471

[52] Ye FG,Cao ZG,Chen DN.Cytidine deaminase axis modulated by miR-484 differentially regulates cell proliferation and chemoresistance in breast cancer..Cancer Res2015;75:1504-15

[53] Rajabpour A,Mahmoodzadeh H,Rajaei F.MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells..Cancer Chemother Pharmacol2017;80:765-75

[54] Frese KK,Cook N,Lolkema MP.nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer..Cancer Discov2012;2:260-9 PMCID:PMC4866937

[55] McCormack JJ,Liu PS,Driscoll JS.Inhibition of cytidine deaminase by 2-oxopyrimidine riboside and related compounds..Biochem Pharmacol1980;29:830-2

[56] Betts L,Short SA,Carter CW Jr.Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex..J Mol Biol1994;235:635-56

[57] Zhou L,Connolly BA,Hurd PJ.Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases..J Mol Biol2002;321:591-9 PMCID:PMC2713825

[58] Hanze AR.Nucleic acids. IV. The catalytic reduction of pyrimidine nucleosides (human liver deaminase inhibitors)..J Am Chem Soc1967;89:6720-5

[59] Beumer JH,Gilbert JA,Yellow-Duke AE.Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice..Cancer Chemother Pharmacol2011;67:421-30 PMCID:PMC2954253

[60] Ferraris D,Delahanty G,Alt J.Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase..J Med Chem2014;57:2582-8

[61] Chung SJ,Verdine GL.Structure of human cytidine deaminase bound to a potent inhibitor..J Med Chem2005;48:658-60

[62] Weizman N,Shabtay-Orbach A,Binenbaum Y.Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase..Oncogene2014;33:3812-9

[63] Amit M.Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase..Oncoimmunology2013;2:e27231 PMCID:PMC3912006

[64] Eckford PD.ABC efflux pump-based resistance to chemotherapy drugs..Chem Rev2009;109:2989-3011

[65] Goodell MA,Kim H,DeMaria M.Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species..Nat Med1997;3:1337-45

[66] Fukuda K,Ohashi M,Kitajima M.Tumor initiating potential of side population cells in human gastric cancer..Int J Oncol2009;34:1201-7

[67] Borst P.Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what?.Open Biol2012;2:120066 PMCID:PMC3376736

[68] Polgar O.ABC transporters in the balance: is there a role in multidrug resistance?.Biochem Soc Trans2005;33:241-5

[69] Bergman AM,Jensen PB,Veerman G.Collateral sensitivity to gemcitabine (2’,2’-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines..Biochem Pharmacol2001;61:1401-8

[70] Bergman AM,Talianidis I,Loves WJ.Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines..Br J Cancer2003;88:1963-70 PMCID:PMC2741118

[71] Adema AD,Smid K,Scheffer GL.Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine..Springerplus2014;3:732 PMCID:PMC4320143

[72] Rudin D,Niu N,Gilbert JA.Gemcitabine cytotoxicity: interaction of efflux and deamination..J Drug Metab Toxicol2011;2:1-10 PMCID:PMC3144579

[73] Bouffard DY,Momparler RL.Kinetic studies on 2’,2’-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase..Biochem Pharmacol1993;45:1857-61

[74] Wang L,Herrstrom Sjoberg A,Bergman T.Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates..FEBS Lett1999;443:170-4

[75] Saiki Y,Fujimura H,Kudo Y.DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells..Biochem Biophys Res Commun2012;421:98-104

[76] Nakano T,Kudo C,Mizuguchi Y.Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK..Biochem Biophys Res Commun2015;464:1084-9

[77] Tang K,Bai Z,Guo W.Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression..Oncol Rep2011;25:963-70

[78] Funamizu N,Kamata Y,Uwagawa T.Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?.Oncol Rep2010;23:471-5

[79] Sierzega M,Kulig P,Kulig J.Prognostic implications of expression profiling for gemcitabine-related genes (hENT1, dCK, RRM1, RRM2) in patients with resectable pancreatic adenocarcinoma receiving adjuvant chemotherapy..Pancreas2017;46:684-9

[80] Ohmine K,Ohtsuki S,Ohtsuka H.Quantitative targeted proteomics of pancreatic cancer: Deoxycytidine kinase protein level correlates to progression-free survival of patients receiving gemcitabine treatment..Mol Pharm2015;12:3282-91

[81] Costantino CL,Kuwano Y,Kennedy EP.The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase..Cancer Res2009;69:4567-72 PMCID:PMC2744447

[82] Tatarian T,Leiby BE,Jimbo M.Cytoplasmic HuR status predicts disease-free survival in resected pancreatic cancer: a post-hoc analysis from the International Phase III ESPAC-3 Clinical Trial..Ann Surg2018;267:364-9 PMCID:PMC6815674

[83] Slusarczyk M,Balzarini J,Jiang WG.Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development..J Med Chem2014;57:1531-42

[84] Blagden SP,Suppiah P,Patel M.Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study..Br J Cancer2018;119:815-22 PMCID:PMC6189138

[85] McNamara MG,Doherty M,Cosgrove D.NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121)..Future Oncol2020;

[86] Daifuku R,Stackhouse M.Vitamin E phosphate nucleoside prodrugs: a platform for intracellular delivery of monophosphorylated nucleosides..Pharmaceuticals (Basel)2018;11: PMCID:PMC5874712

[87] Shewach DS,Chang E,Lawrence TS.Metabolism of 2’,2’-difluoro-2’-deoxycytidine and radiation sensitization of human colon carcinoma cells..Cancer Res1994;54:3218-23

[88] Gregoire V,De Bast M,De Coster B.Role of deoxycytidine kinase (dCK) activity in gemcitabine’s radioenhancement in mice and human cell lines in vitro..Radiother Oncol2002;63:329-38

[89] Van Den Neste E,Cardoen S,Frankard J.Activation of deoxycytidine kinase by UV-C-irradiation in chronic lymphocytic leukemia B-lymphocytes..Biochem Pharmacol2003;65:573-80

[90] Sigmond J,Kreder NC,van Bree C.Enhanced activity of deoxycytidine kinase after pulsed low dose rate and single dose gamma irradiation..Nucleosides Nucleotides Nucleic Acids2006;25:1177-80

[91] Yang C,Hao J,Guo X.Deoxycytidine kinase regulates the G2/M checkpoint through interaction with cyclin-dependent kinase 1 in response to DNA damage..Nucleic Acids Res2012;40:9621-32 PMCID:PMC3479177

[92] Beyaert M,Van Den Neste E.A crucial role for ATR in the regulation of deoxycytidine kinase activity..Biochem Pharmacol2016;100:40-50

[93] McSorley T,Hazra S,Konrad M.Mimicking phosphorylation of Ser-74 on human deoxycytidine kinase selectively increases catalytic activity for dC and dC analogues..FEBS Lett2008;582:720-4 PMCID:PMC2636680

[94] Sharma B,Adiseshaiah PP.Nanotechnology as a delivery tool for precision cancer therapies..AAPS J2017;19:1632-42

[95] Elechalawar CK,Shankarappa P,Figg WD.Targeting pancreatic cancer cells and stellate cells using designer nanotherapeutics in vitro..Int J Nanomedicine2020;15:991-1003 PMCID:PMC7025663

[96] Torres C.Pancreatic cancer subtypes: a roadmap for precision medicine..Ann Med2018;50:277-87 PMCID:PMC6151873